Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05843994
Other study ID # 2023-5810
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date February 13, 2023
Est. completion date June 30, 2024

Study information

Verified date March 2024
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study, an artificial intelligence model to detect squamous cell carcinomas (SCC) on photos of recessive dystrophic epidermolysis bullosa (RDEB) skin is developed. The ultimate goal is to integrate this model into an app for patients and physicians, to help detect SCCs in RDEB early. SCCs which rapidly metastasize are the main cause of death in adults with RDEB. The earlier an SCC is recognized, the easier it can be removed and the better the outcome. AI leverages computer science to perform tasks that typically require human intelligence and has recently been used to identify skin cancers based on images. We are currently developing an AI approach for early detection of SCC and distinction of malignancy from chronic wounds and other RDEB skin findings. The aim is to create a web application for patients with RDEB to upload images of their skin and get an output as to SCC present/ no SCC. This will be especially valuable for patients with difficult access to medical expertise and those who are hesitant to allow full skin examination at each visit, often because of fear of biopsies. Thus, this project will directly benefit patients by allowing early recognition of SCCs and will empower patients and their families by providing a home use tool. So far, the study team has mainly used professional images (photographs taken in hospital settings by physicians, nurses, and clinical photographers) of both SCCs in RDEB and images of RDEB skin without SCC to develop and train the AI model. The images that are expected in a real-life setting will mostly be pictures taken by patients or family members with their phones or digital cameras. These images have different properties regarding resolution, focus, lighting, and backgrounds. Incorporating such images will be crucial in the upcoming phases of model development-testing and validation-for the web application be a success for patients.


Description:

This project will enroll adolescents and adults with RDEB and history of at least one SCC. The survey and consents will be provided in English, Spanish, German, French, Arabic, Chinese, and Russian. The study team is inviting people with RDEB around the world to participate and are hoping that approximately 100 people will provide images. Participants will be asked to complete the survey and upload photographs of SCC(s) using the links below. Depending on the number of SCCs they have had and the number of photos they want to provide, the survey will take approximately 15-20 minutes to complete. To participate in this study, please follow this link: https://redcap.nubic.northwestern.edu/redcap/surveys/?s=JH9LHR4CC4R4H3HN


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date June 30, 2024
Est. primary completion date November 30, 2023
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - patient with recessive dystrophic epidermolysis bullosa - patient with history of cutaneous squamous cell carcinoma - patient consent for upload and use of clinical data and photographs Exclusion Criteria: - Patients who do not agree to upload and use of photographs and clinical data

Study Design


Related Conditions & MeSH terms


Intervention

Other:
online survey
Participants will complete an online survey and submit photographs.

Locations

Country Name City State
United States Department of Dermatology, Northwestern University Feinberg School of Medicine and Lurie Children's Hospital Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
Northwestern University Epidermolysis Bullosa Research Partnership

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent agreement of the presence or absence of squamous cell carcinoma (SCC) on the skin in photographs as detected by the App versus confirmed physician diagnosis one day survey
See also
  Status Clinical Trial Phase
Completed NCT01263379 - Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa Phase 1/Phase 2
Completed NCT01716169 - Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care N/A
Completed NCT00951964 - Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate) Phase 2
Recruiting NCT03269474 - Computational Drug Repurposing for All EBS Cases
Recruiting NCT01019148 - Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Completed NCT03241628 - Proof of Concept Study for a Dressing Glove N/A
Not yet recruiting NCT05390073 - Growth Hormone in EB
Recruiting NCT04213703 - A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
Not yet recruiting NCT06177353 - Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo Analysis and the Impact of Placental Stem Cells in Vitro
Recruiting NCT06007235 - CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa N/A
Active, not recruiting NCT05033574 - The State of Sexual Development in Children With Inherited Epidermolysis Bullosa
Completed NCT04908215 - INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa Phase 2
Terminated NCT00587223 - Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB) Phase 3
Active, not recruiting NCT04171661 - Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa Early Phase 1
Terminated NCT00533572 - Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer N/A
Completed NCT00904163 - Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa N/A
Recruiting NCT03786237 - Rigosertib for RDEB-SCC Phase 1/Phase 2